EnGeneIC recognised for nanocell platform

Latest News

Australian clinical-stage biopharmaceutical company EnGeneIC has been featured in the publication InsightsCare as one of the ten most innovative healthcare nanotech companies to watch. 

The company is developing its EDV nanocell platform for use as a targeted cyto-immunotherapy in cancer.

It is now in Phase 2a clinical trials in patients with intractable cancers, including patients with metastatic pancreatic cancer, and is planning to commence further clinical trials in Australia and the US.

The December 2019 Issue of InsightsCare is focused on the convergence of nanotechnology and medicine.

EnGeneIC was selected based on the its development of the EDV nanocell. The technology can carry a payload directly to cancer cells while at the same time promoting an anti-tumour immune response. 

Other companies described in the article include Spano Nanomedical, Nanoshell Company, ExonanoRNA and Zylo Therapeutics.